MIRA PHARMACEUTICALS, INC. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by MIRA Pharmaceuticals, Inc. on October 16, 2025, reporting a significant equity financing event. The Company is incorporated in Florida and its common stock trades on The Nasdaq Capital Market under the symbol "MIRA".
Key Financial Metrics
- Shares Sold: 1,751,000 shares of common stock.
- Average Price: $2.19 per share.
- Premium: 66% premium to the prior day's closing price.
- Gross Proceeds: Approximately $3,835,485 (prior to fees and expenses).
- Facility Used: At-the-market equity offering facility.
- Intermediary: Rodman & Renshaw via the StockBlock platform.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions, as this report focuses solely on the equity transaction.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of gross proceeds of approximately $3.84 million. The transaction was executed at a significant premium to the market price, indicating strong institutional demand at the time of the sale.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity sale. The transaction did not include any warrants.
Investor Verification Checklist
- Verify the net proceeds after deducting fees and expenses from the gross amount of $3,835,485.
- Confirm the updated total number of outstanding shares following the issuance of 1,751,000 new shares.
- Review the Company's use of proceeds to ensure alignment with stated capital allocation strategies.
- Check for any subsequent filings regarding the dilution impact on existing shareholders.